To bring to market by 2022 a drug (NOX66) that:
- sensitises most forms of cancer to radiotherapy and chemotherapy
- delivers improved survival outcomes for most cancer patients
- becomes a standard-of-care drug in cancer therapy
To develop a pipeline of non-oncology drugs, capable of crossing into the brain, with first-in-class activity against a number of common community diseases/disorders of significant unmet.
To view Presentation please download PDF attached:
Download this document